Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Leber Congenital Amaurosis (LCA) – Overview
Leber Congenital Amaurosis (LCA) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Leber Congenital Amaurosis (LCA) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Leber Congenital Amaurosis (LCA) – Companies Involved in Therapeutics Development
Leber Congenital Amaurosis (LCA) – Drug Profiles
Leber Congenital Amaurosis (LCA) – Dormant Projects
Leber Congenital Amaurosis (LCA) – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Leber Congenital Amaurosis (LCA), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Leber Congenital Amaurosis (LCA), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Leber Congenital Amaurosis (LCA) – Pipeline by Atsena Therapeutics Inc, 2022
Leber Congenital Amaurosis (LCA) – Pipeline by Editas Medicine Inc, 2022
Leber Congenital Amaurosis (LCA) – Pipeline by Generation Bio Co, 2022
Leber Congenital Amaurosis (LCA) – Pipeline by Hubble Therapeutics Inc, 2022
Leber Congenital Amaurosis (LCA) – Pipeline by Huida (Shanghai) Biotechnology Co Ltd, 2022
Leber Congenital Amaurosis (LCA) – Pipeline by IVERIC bio Inc, 2022
Leber Congenital Amaurosis (LCA) – Pipeline by LuxFiat Therapeutics LLC, 2022
Leber Congenital Amaurosis (LCA) – Pipeline by MeiraGTx Holdings Plc, 2022
Leber Congenital Amaurosis (LCA) – Pipeline by Ocugen Inc, 2022
Leber Congenital Amaurosis (LCA) – Pipeline by Odylia Therapeutics Inc, 2022
Leber Congenital Amaurosis (LCA) – Pipeline by Opus Genetics Inc, 2022
Leber Congenital Amaurosis (LCA) – Pipeline by ProQR Therapeutics NV, 2022
Leber Congenital Amaurosis (LCA) – Pipeline by Variant, 2022
Leber Congenital Amaurosis (LCA) – Dormant Projects, 2022